GLP-1s and Fatty Liver Disease: What the ESSENCE Trial Actually Showed

MASH stands for metabolic dysfunction-associated steatohepatitis — the stage of fatty liver disease where fat in the liver has triggered inflammation and cell damage. Think of it as a two-step ladder. The first rung is MASLD (metabolic dysfunction-associated steatotic liver disease), formerly called NAFLD: fat has accumulated in liver cells, but the liver is not yet inflamed. Roughly 1 in 3 adults worldwide is on this rung, and most will never progress further.

The second rung is MASH. Here the fat is doing damage. Immune cells move in, liver cells swell and die, and the liver starts laying down scar tissue — fibrosis — in response. About 1 in 20 adults has MASH. It is the stage that matters clinically, because fibrosis is what predicts cirrhosis, liver failure, and liver cancer down the line.

The terminology changed in 2023, which is why you may see all four acronyms used interchangeably. NAFLD became MASLD and NASH became MASH, in part to move away from defining the condition by what it is *not* (non-alcoholic) and toward what actually drives it: metabolic dysfunction — insulin resistance, visceral fat, high triglycerides, and high blood pressure.

The cruel thing about MASH is how quiet it is. There are usually no symptoms until fibrosis is advanced. Most people find out because a routine blood panel shows elevated liver enzymes (ALT and AST), or an abdominal ultrasound ordered for something else shows a "bright" or "fatty" liver. If you have insulin resistance, this is worth asking your doctor about directly — the [connection between insulin resistance and metabolic health](/blog/glp1-menopause-insulin-resistance-the-connection) runs straight through the liver.

ESSENCE tested whether semaglutide 2.4 mg — the same dose and molecule sold as Wegovy — could reverse liver damage in people who already had biopsy-confirmed MASH with moderate to advanced fibrosis (stage F2 or F3).

This was a large, randomized, double-blind, placebo-controlled phase 3 trial. Participants received either weekly semaglutide 2.4 mg or placebo for 72 weeks. Crucially, the outcome was measured by liver biopsy, not a blood marker or scan. Two pathologists who did not know which treatment each person received read the before-and-after tissue samples. Biopsy is the strictest possible standard in liver research, and it is why this trial carries so much weight.

The trial had two co-primary endpoints, both assessed at week 72:

1. Resolution of steatohepatitis with no worsening of fibrosis — did the inflammation go away without the scarring getting worse? 2. Improvement in liver fibrosis with no worsening of steatohepatitis — did the scarring measurably reverse without the inflammation getting worse?

Setting both endpoints matters. A drug that reduces inflammation while scarring quietly advances is not a win. ESSENCE was designed so semaglutide had to move both needles in the right direction, or at minimum hold one steady while improving the other. The results were published in the New England Journal of Medicine in 2025 (Sanyal et al.).

The headline number: 62.9% of participants on semaglutide had their steatohepatitis resolve with no worsening of fibrosis, compared with 34.3% on placebo (ESSENCE, NEJM 2025). That is nearly double the placebo rate.

On the second endpoint, 36.8% of the semaglutide group showed improvement in liver fibrosis with no worsening of steatohepatitis, versus 22.4% on placebo. Fibrosis is notoriously stubborn — scar tissue does not usually un-scar — so a 14-point absolute advantage on a biopsy-confirmed endpoint is a meaningful result.

Most impressive is the combined endpoint: 32.7% of people on semaglutide achieved both MASH resolution and fibrosis improvement, versus 16.1% on placebo. Roughly one in three people hit the full double win.

One number worth holding onto: the placebo group did not do nothing. A third of them improved too. That is not a fluke — everyone in the trial received lifestyle counseling, and MASH is genuinely responsive to diet, movement, and modest weight loss. The drug roughly doubled what lifestyle change alone achieved. It did not replace it.

Mean weight loss on semaglutide in the trial was 10.5% at week 72 — lower than the ~15% seen in the STEP obesity trials, likely because the ESSENCE population was selected for liver disease rather than BMI. This raises the obvious question of whether the liver improved simply because people lost weight.

Partly, but researchers do not think that is the whole story. Weight loss is a well-established treatment for MASH: losing 7-10% of body weight reliably reduces liver fat and often resolves inflammation. Semaglutide delivered 10.5% average weight loss in ESSENCE, squarely in the therapeutic range. So some of the benefit is almost certainly weight-driven.

But several signals suggest additional mechanisms are at work. Semaglutide improves insulin sensitivity independently of weight, and insulin resistance is the engine that drives fat into the liver in the first place. It lowers circulating triglycerides and free fatty acids, reducing the raw material the liver has to store. And GLP-1 signaling appears to dampen systemic inflammation — participants in ESSENCE showed improvements in inflammatory markers.

There is also a timing argument. Liver enzyme improvements in GLP-1 trials tend to appear early, sometimes before substantial weight loss has occurred. That pattern is hard to explain by weight alone.

What the trial cannot tell us is how much of each. Untangling "drug effect" from "weight loss effect" would require comparing semaglutide against a group that lost the same amount of weight by other means — a study that has not been done at this scale. The practical answer for now: it works, and the mechanism is probably both. If you want the underlying biology, we cover [how GLP-1 medications work](/blog/how-glp1-medications-work-mechanism-explained) in detail.

Because estrogen is quietly protective of the liver, and losing it changes where your body stores fat.

Before menopause, women store fat preferentially in the hips and thighs — subcutaneous fat, which is metabolically relatively harmless. As estradiol falls through perimenopause and after, storage shifts toward the abdomen and the visceral compartment: fat packed around and inside the organs, including the liver. This is the same shift behind the [belly fat redistribution so many women notice in midlife](/blog/glp1-menopause-visceral-fat-why-belly-fat-shifts).

Visceral fat is not passive. It drains directly into the portal vein, delivering free fatty acids and inflammatory signals straight to the liver. Combine that with the insulin resistance that also tends to worsen after menopause, and you get the exact conditions that push a liver from mildly fatty toward inflamed.

The epidemiology reflects this. Before age 50, fatty liver disease is more common in men. After 50, the gap closes and in some datasets reverses. MASH-related cirrhosis is now one of the leading indications for liver transplant in women in the United States.

This is not a reason for alarm — it is a reason to ask for a liver panel. If you are in perimenopause or postmenopause and carrying central weight, an ALT/AST check and a FIB-4 score (a simple calculation from age, liver enzymes, and platelet count) cost almost nothing and can flag risk years before symptoms appear.

Yes, if any of the following apply to you. MASH screening is underused precisely because the disease is silent.

Ask for a liver panel and a FIB-4 score if you have:

• •Type 2 diabetes or prediabetes — the single strongest risk factor
• •A BMI over 30, or central weight gain regardless of BMI
• •High triglycerides or low HDL cholesterol
• •Been told at any point that you have a "fatty liver" on an ultrasound or CT
• •Polycystic ovary syndrome (PCOS)
• •A family history of cirrhosis or unexplained liver disease

The FIB-4 score is worth knowing by name. It is calculated from your age, AST, ALT, and platelet count — all standard on routine bloodwork. A score below 1.3 makes advanced fibrosis unlikely. Above 2.67 warrants referral to a hepatologist. In between, a FibroScan (a painless ultrasound-based elastography test that measures liver stiffness) is usually the next step. Biopsy is now reserved for cases where imaging is ambiguous.

A note on alcohol: MASH is defined as liver disease *not* primarily caused by alcohol, but alcohol makes it worse. If you have MASLD or MASH, cutting alcohol is one of the highest-yield changes available. Many women on GLP-1 medications find their desire to drink drops on its own, which we cover in [alcohol on GLP-1](/blog/alcohol-on-glp1-during-menopause-why-it-hits-harder).

As of 2026, semaglutide 2.4 mg (Wegovy) received FDA accelerated approval for MASH with moderate to advanced fibrosis on the strength of the ESSENCE interim analysis. This makes it one of a very small number of approved treatments for a condition that had essentially none a few years ago.

It is not the only one. Resmetirom (Rezdiffra), a thyroid hormone receptor-beta agonist, was approved in 2024 for MASH with F2-F3 fibrosis and works through an entirely different pathway. The two drugs have not been compared head to head, and it is plausible that combination therapy will be studied.

A few practical caveats. Accelerated approval means the FDA accepted a surrogate endpoint — biopsy improvement — as reasonably likely to predict clinical benefit. Confirmatory data on hard outcomes like cirrhosis, transplant, and death are still being collected; the full ESSENCE trial continues to 240 weeks. Insurance coverage for a MASH indication is still uneven and often requires documented fibrosis staging.

And the obvious point: semaglutide is not a substitute for the rest of it. Everyone in ESSENCE received lifestyle counseling. Protein intake, resistance training, alcohol reduction, and sleep all independently affect liver fat. The medication multiplies those efforts rather than replacing them — the same principle that applies to [preserving muscle while losing weight on a GLP-1](/blog/strength-training-on-glp1-how-to-preserve-muscle-while-losing-weight).